Stock NXTC NEXTCURE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases NextCure, Inc.

Equities

NXTC

US65343E1082

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-05-03 pm EDT 		5-day change 1st Jan Change
1.53 USD +2.68% Intraday chart for NextCure, Inc. +13.33% +34.21%
May. 02 NextCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 08 NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
GL
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
GL
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
GL
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
GL
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
GL
NextCure : March 2024 Corporate Presentation
PU
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
GL
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
GL
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
AQ
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
GL
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
GL
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
AQ
Chronic Myelomonocytic Leukaemia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)
AQ
NextCure Provides Year-End Clinical Pipeline Updates
GL
NextCure Provides Year-End Clinical Pipeline Updates
AQ
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
GL
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
AQ
NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
GL
NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
GL
NextCure : NC605 ASBMR Poster 2023
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NXTC Stock
  4. News NextCure, Inc.
  5. Press Releases